Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) 3-Year Book Growth Rate : 7.00% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year Book Growth Rate?

Sunshine Guojian Pharmaceutical (Shanghai) Co's Book Value per Share for the quarter that ended in Mar. 2025 was ¥9.20.

During the past 12 months, Sunshine Guojian Pharmaceutical (Shanghai) Co's average Book Value per Share Growth Rate was 13.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was 7.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was 9.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Sunshine Guojian Pharmaceutical (Shanghai) Co was 34.70% per year. The lowest was 2.40% per year. And the median was 9.40% per year.

Competitive Comparison of Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

https://www.3s-guojian.com

Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.

Executives

Weng Zhi Bing	Core technical personnel
Huang Hao Min	Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines